Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects
- 8 February 2014
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 38 (3) , 372-379
Abstract
In platelets, thrombin receptor signaling depends upon the release of adenosine diphosphate and subsequent activation at purinergic subtype Y (P2Y) receptors. The purpose of this study is to evaluate the influence of specific P2Y12 polymorphisms on platelet reactivity in healthy subjects mediated by thrombin receptor activating peptide (TRAP). We recruited a total of 29 healthy volunteers who had been previously genotyped for two polymorphisms of the P2Y12 receptor: the H2 haplotype (rs2046934) and 34C>T (rs6785930). Flow cytometry and the VerifyNow assay were used to assess platelet activation and aggregation stimulated by TRAP in the presence and absence of specific receptor antagonists for the P2Y1, P2Y12, and thromboxane A2 receptors. We identified a significant recessive effect of the P2Y12-receptor H2 haplotype on TRAP-induced flow cytometry. Specifically, H2/H2 carriers (n = 5) demonstrated a significant reduction in both glycoprotein IIb/IIIa receptor activation (p < 0.001) and CD62P expression (p = 0.035). While the VerifyNow assay did not reveal any effect of haplotype on TRAP-mediated platelet aggregation (p = 0.72), the H2/H2 subjects demonstrated greater platelet inhibition in the presence of cangrelor, a specific receptor antagonist for the P2Y12 receptor (p = 0.023). No consistent effects of the separate 34C>T genotype (rs6785930) were demonstrated under the conditions evaluated. The findings of this study suggest a potential association between P2Y12-receptor H2/H2 carriers and reduced platelet function mediated by TRAP in healthy volunteers.Keywords
This publication has 31 references indexed in Scilit:
- Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialThe Lancet, 2012
- Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonistsNature Genetics, 2010
- Common Variation in the Platelet Receptor P2RY12 Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary InterventionsCirculation: Cardiovascular Genetics, 2009
- A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathwaysBlood, 2009
- Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrelCoronary Artery Disease, 2009
- Coexisting Polymorphisms of P2Y12 and CYP2C19 Genes as a Risk Factor for Persistent Platelet Activation With ClopidogrelCirculation Journal, 2008
- Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y12 , and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery DiseaseStroke, 2005
- Dimorphism in the P2Y1 ADP Receptor Gene Is Associated With Increased Platelet Activation Response to ADPArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With
P2Y
12
Gene Sequence Variations in Healthy SubjectsCirculation, 2003
- An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRNBlood, 2003